Contact us to find out if we have the data you need. Having offices around the globe, we are open 24 hours a day, 5 days a week with multiple language support. Please visit our Contact page to see which office is open right now!

Most comprehensive report covering worldwide markets, Data-intensive research - An imperative for the serious player!, Designed to empower the quality conscious executive more…

European Market for Osteoporosis Therapeutics in 2003 & 2004: Market Share more…

Abstract Overview Introduction The osteoporosis market is due a major upheaval when market leader Fosamax (alendronate) loses its US patent. The resultant heightened c more…

The U.S. Multiple Myeloma Market is a rapidly progressing field that is set to generate over $3 billion in revenue in the coming years. The market has witnessed unprecedented more…

Overview Introduction The 2004 withdrawal of Vioxx from the global market had a negative effect on the COX-2 class, with a 44% fall in Celebrex sales for osteoarthritis in more…

Overview Introduction Osteoarthritis (OA) is characterized by the progressive destruction of articular joints and is a major cause of pain in Western populations. OA is the mo more…

Introduction The osteoporosis market has grown near% per year sin00, presenting many opportunities for drug manufacturers. However, several effective, well-established, and more…

This research service analyzes emerging medical device technologies for the spine market and their impact in the healthcare market. more…

This Frost & Sullivan research service entitled U.S. Bone Growth and Spinal Fusion Stimulators Markets provides an overview of the bone stimulators industry, along with a more…

This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years more…

Partneringdesk Deals and alliances in musculoskeletal diseases Partneringdesk deals and alliances in musculoskeletal diseases provides an in-depth view of 370 deals and more…

Overview Introduction Osteoarthritis offers a very attractive commercial target in terms of patient potential, and the explosion in new disease modifying drugs in rheumatoid a more…

Overview Introduction The global Rheumatoid Arthritis (RA) market has experienced extraordinary growth over the last decade. This market valued at $4.14 billion in 2004, shows more…

Overview Introduction The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving over the last decade. Currently, the newer targeted biologic therapies against more…

In This Issue... The demand for drugs to treat osteoporosis will grow substantially during the next ten years. This growth will be driven by increasing market penetration more…

Market Intelligence In 2004, the US soft tissue repair market was valued at nearly $380 million. Driven primarily by product innovation, favorable demographics, and the overal more…

Analysis of WHI impact on the osteoporosis and HRT market and portfoliomanagement strategy in hormone therapy more…

The total orthopaedic drug, implant and device market is expected to reach $44 billion by end of 2004. Rising at an average annual growth rate (AAGR) of 11%, the market is more…

The MS market is highly lucrative and competitive sector with only five marketed drugs worth $2.8billion in 2003. However, the dynamics of the market will shift from 2005 more…

The report provides essential business intelligence on the latest spinal product developments, with detailed company profiles and market forecasts that will be invaluable to more…

This Frost & Sullivan research service analyzes the key drivers and challenges influencing the U.S. arthritis therapies market. Product and pricing trends coupled with patient more…

Osteoporosis therapy is the focus of attention of significant R&D activity, with drugs in development both in existing classes offering advantages over marketed products and more…

The treatment of RA has changed significantly as treatment shifts towards early, aggressive management of the disease. Although guidelines support early use of DMARDs, more…

Research is predominantly at an early discovery or pre-clinical stage, with only three products in human trials. P&Gs MMP inhibitor, although at an early stage, has shown more…

Osteoporosis, with an estimated prevalent population of over 127 million in the seven major markets and valued at around $7 billion in 2002, presents a commercially attractive more…

This report discusses the world market for rheumatoid arthritis therapeutics in terms of its potential in the growing older population in the United States as opposed to a more…

As negative trial results edge the HRT market into decline, osteoporosis players have an opportunity to gain market share. Drugs with multiple indications and convenient more…

This analysis focuses on the changing landscape of the commercial environment in the global arthritis market and investigates key strategies required to succeed. Analysis of more…

Spinal disc replacement represents an emerging technology that many consider to be one of the greatest advances in orthopaedics in many years, with the potential to more…

This report focuses on the bone- and joint-related applications of and markets for the various types of regenerative medicine currently available and projected to be more…

Kyphoplasty, which involves the use of a balloon tamp to expand fractured bone, and the use of Kyphon's proprietary technology for this procedure, is experiencing rapid more…

Women' s Health: Worldwide Prescription Drug Markets is a comprehensive study of the pharmaceutical markets aimed at diseases and conditions that affect women. more…

Driven by the globally aging population, the incidence of OA and RA will increase significantly over the next seven years. The efforts to find cures for these diseases will more…

Metastases to the bone occur in up to 75% of patients with breast and prostate cancer and can severely affect quality of life. This Brief examines trends in the bone more…

Currently available therapies for multiple myeloma is effective in high dose, but is associated with severe toxicity. In addition, all patients eventually relapse. This has more…

The introduction of bone morphogenic proteins (BMPs) can turn the bone graft market on its head. Though overpriced, they have the potential to eclipse all other products more…

Introduction The long-standing unmet need of the osteoporosis market has been for improved adherence to treatment. Two pipeline products, Amgen's Denosumab and Novartis' more…